Advances in Development, Characterisation and Application of Nasal Drug Delivery Systems

Hafner, Anita

doi:10.3390/pharmaceutics14081562

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main challenges of nicardipine IN solution were the dose inconsistency and low bioavailability as a dose fraction flowing into the gastrointestinal tract via the internal nares and the pharynx [56]. These constitute common issues in nasal delivery, highlighting the need for pioneering formulations with targeted deposition and more efficient absorption into the nasal cavity [58]. Considering that clevidipine is endorsed for blood pressure control in patients with acute ischemic stroke, it seems that CCBs may be recommended in specific hypertensive states (e.g., acute aortic syndromes).…”

Section: Hypertensive Crisismentioning

confidence: 99%

Nose-to-Heart Approach: Unveiling an Alternative Route of Acute Treatment

Papakyriakopoulou,

Valsami,

Kadoglou

2024

Biomedicines

View full text Add to dashboard Cite

Intranasal (IN) administration has emerged as a novel approach for rapid systemic absorption, with potential applicability in the management of acute cardiovascular events. This review explores the evolution of IN cardiovascular pharmacotherapy, emphasizing its potential in achieving systemic effects and bypassing the first-pass metabolism associated with oral administration. The extensive vascularization of nasal mucosa and a porous endothelial basement membrane facilitate efficient drug absorption into the bloodstream. The IN route ensures a critical swift onset of action, which allows self-administration in at-home settings. For instance, etripamil nasal spray, a first-in-class formulation, exemplifies the therapeutic potential of this approach in the treatment of spontaneous supraventricular tachycardia. The review critically assesses studies on IN formulations for angina, acute myocardial infarction, hypertensive episodes, and cardiac arrhythmias. Preclinical evaluations of beta-blockers, calcium-channel blockers, and antianginal drugs demonstrate the feasibility of IN administration for acute cardiovascular events. A small number of clinical trials have revealed promising results, emphasizing the superiority of IN drug delivery over oral administration in terms of bioavailability and onset of action. Unambiguously, the limited clinical trials and patient enrollment pose challenges in generalizing experimental outcomes. However, the nose-to-heart approach has clinical potential.

show abstract

Section: Hypertensive Crisismentioning

confidence: 99%

Nose-to-Heart Approach: Unveiling an Alternative Route of Acute Treatment

Papakyriakopoulou,

Valsami,

Kadoglou

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Recently, innovative nasal drug delivery systems have been developed to maximize its bioavailability by enhancing the solubility, permeability, and retention time at the nasal mucosa. For example, specific formulations have been investigated for nasal drug delivery, such as soft nano-vesicular systems, microsphere/inert carrier dry powder platform for brain-targeted delivery, and binary composite solid microparticles as nasal permeation enhancers ( Hafner, 2022 ). Unlike these strategies, CPPs per se are able to internalize live cells and are peptide enhancers that mediate the transepithelial transport of large molecules without affecting cellular integrity.…”

Section: Feasibility Of Cpp-mediated Nasal Drug Deliverymentioning

confidence: 99%

Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides

Maeng

Lee

2022

Front. Pharmacol.

View full text Add to dashboard Cite

The intranasal route has emerged as a promising strategy that can direct delivery of drugs into the systemic circulation because the high-vascularized nasal cavity, among other advantages, avoids the hepatic first-pass metabolism. The nose-to-brain pathway provides a non-invasive alternative to other routes for the delivery of macromolecular therapeutics. A great variety of methodologies has been developed to enhance the efficiency of transepithelial translocation of macromolecules. Among these, the use of cell-penetrating peptides (CPPs), short protein transduction domains (PTDs) that facilitate the intracellular transport of various bioactive molecules, has become an area of extensive research in the intranasal delivery of peptides and proteins either to systemic or to brain compartments. Some CPPs have been applied for the delivery of peptide antidiabetics, including insulin and exendin-4, for treating diabetes and Alzheimer’s disease. This review highlights the current status of CPP-driven intranasal delivery of peptide drugs and its potential applicability as a universal vehicle in the nasal drug delivery.

show abstract

“…et al, 2008 ; Mura et al, 2022 ). Once an IN-DDS is developed, several experiments are required to study the interfering factors that affect the rate and extent of drug diffusion, mimicking the normal physiology of drug access to the brain ( Bartos et al, 2021 ; Hafner, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Synthesis of an insulin-loaded mucoadhesive nanoparticle designed for intranasal administration: focus on new diffusion media

Jamshidnejad-Tosaramandani,

Kashanian,

Karimi

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Intranasal administration is a drug delivery approach to provide a non-invasive pharmacological response in the central nervous system with relatively small peripheral side effects. To improve the residence time of intranasal drug delivery systems in the nasal mucosa, mucoadhesive polymers (e.g., chitosan) can be used. Here, insulin-loaded chitosan nanoparticles were synthesized and their physiochemical properties were evaluated based on requirements of intranasal administration. The nanoparticles were spherical (a hydrodynamic diameter of 165.3 nm, polydispersity index of 0.24, and zeta potential of +21.6 mV) that granted mucoadhesion without any noticeable toxicity to the nasal tissue. We applied a new approach using the Krebs–Henseleit buffer solution along with simulated nasal fluid in a Franz’s diffusion cell to study this intranasal drug delivery system. We used the Krebs–Henseleit buffer because of its ability to supply glucose to the cells which serves as a novel ex vivo diffusion medium to maintain the viability of the tissue during the experiment. Based on diffusion rate and histopathological endpoints, the Krebs–Henseleit buffer solution can be a substituent solution to the commonly used simulated nasal fluid for such drug delivery systems.

show abstract

Advances in Development, Characterisation and Application of Nasal Drug Delivery Systems

Abstract: Nasal drug administration is being extensively investigated for local and systemic drug delivery, brain targeting and mucosal vaccination [...]

Cited by 3 publications

References 7 publications

Nose-to-Heart Approach: Unveiling an Alternative Route of Acute Treatment

Nose-to-Heart Approach: Unveiling an Alternative Route of Acute Treatment

Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides

Synthesis of an insulin-loaded mucoadhesive nanoparticle designed for intranasal administration: focus on new diffusion media

Contact Info

Product

Resources

About